These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38735683)

  • 61. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma.
    Mirza AS; Kumar A; Hashmi H; Garcia F; Logothetis CN; Darwin A; Faramand R; Reid K; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Nishihori T; Locke FL; Jain MD
    Transplant Cell Ther; 2021 Mar; 27(3):242.e1-242.e6. PubMed ID: 33781520
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.
    Zhang X; Yang J; Li J; Li W; Song D; Lu XA; Wu F; Li J; Chen D; Li X; Xu Z; Liu S; Li Z; Ying K; Lu P
    Cancer Immunol Immunother; 2022 Mar; 71(3):689-703. PubMed ID: 34365516
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.
    Bailén R; Iacoboni G; Delgado J; López-Corral L; Hernani-Morales R; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Guerra-Domínguez ML; Sánchez-Pina JM; Peña M; Torrent A; Pérez-Martínez A; Bastos-Oreiro M; Reguera-Ortega JL; Martín A; Hernandez-Boluda JC; Martínez-Cibrián N; Sanz J; Briones J; Henriquez HL; Calbacho M; Mussetti A; Sancho JM; Barba P; Kwon M;
    Transplant Cell Ther; 2024 Oct; 30(10):988.e1-988.e11. PubMed ID: 39069076
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study.
    Tun AM; Patel RD; St-Pierre F; Ouchveridze E; Niu A; Thordardottir T; Obasi J; Rosenthal A; Pophali PA; Fenske TS; Karmali R; Ahmed S; Johnston PB
    Am J Hematol; 2024 Sep; 99(9):1712-1720. PubMed ID: 38837403
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
    Zhang Y; Patel RP; Kim KH; Cho H; Jo JC; Jeong SH; Oh SY; Choi YS; Kim SH; Lee JH; Angelos M; Guruprasad P; Cohen I; Ugwuanyi O; Lee YG; Pajarillo R; Cho JH; Carturan A; Paruzzo L; Ghilardi G; Wang M; Kim S; Kim SM; Lee HJ; Park JH; Cui L; Lee TB; Hwang IS; Lee YH; Lee YJ; Porazzi P; Liu D; Lee Y; Kim JH; Lee JS; Yoon DH; Chung J; Ruella M
    Mol Cancer; 2023 Dec; 22(1):200. PubMed ID: 38066564
    [TBL] [Abstract][Full Text] [Related]  

  • 69. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.
    Lorenc R; Shouval R; Flynn JR; Devlin SM; Saldia A; De Abia AL; De Lapuerta MC; Tomas AA; Cassanello G; Leslie LA; Rejeski K; Lin RJ; Scordo M; Shah GL; Palomba ML; Salles G; Park J; Giralt SA; Perales MA; Ip A; Dahi PB
    Transplant Cell Ther; 2024 Oct; 30(10):990-1000. PubMed ID: 38972512
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
    Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
    Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
    Gauthier J; Gazeau N; Hirayama AV; Hill JA; Wu V; Cearley A; Perkins P; Kirk A; Shadman M; Chow VA; Gopal AK; Hodges Dwinal A; Williamson S; Myers J; Chen A; Nagle S; Hayes-Lattin B; Schachter L; Maloney DG; Turtle CJ; Sorror ML; Maziarz RT
    Blood; 2022 Jun; 139(26):3722-3731. PubMed ID: 35439295
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
    Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
    Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study.
    Wang J; Alkrekshi A; Dasari S; Lin HC; Elantably D; Armashi ARA
    Bone Marrow Transplant; 2023 Nov; 58(11):1223-1228. PubMed ID: 37604871
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Kallam A; Vose JM
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
    Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Wang X; Zhang B; Zhang Q; Zhou H; Sun Q; Zhou Y; Li T; Zhou D; Shen Z; Zhang J; Li P; Liang A; Zhou K; Han L; Hu Y; Yang Y; Cao J; Li Z; Xu K; Sang W
    Cancer; 2024 Aug; 130(15):2660-2669. PubMed ID: 38578977
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
    Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M
    Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.
    Chartier M; Filosto S; Peyret T; Chiney M; Milletti F; Budka J; Ndi A; Dong J; Vardhanabhuti S; Mao D; Duffull S; Dodds M; Shen R
    Clin Pharmacokinet; 2024 Sep; 63(9):1283-1299. PubMed ID: 39240498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.